- Home
- CTMX vs AEXA Comparison
CTMX vs AEXA Comparison
Compare CTMX & AEXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- AEXA
- Stock Information
- Founded
- CTMX 2008
- AEXA 2025
- Country
- CTMX United States
- AEXA United States
- Employees
- CTMX N/A
- AEXA N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- AEXA
- Sector
- CTMX Health Care
- AEXA
- Exchange
- CTMX Nasdaq
- AEXA Nasdaq
- Market Cap
- CTMX 596.2M
- AEXA 559.4M
- IPO Year
- CTMX 2015
- AEXA 2025
- Fundamental
- Price
- CTMX $3.39
- AEXA $11.63
- Analyst Decision
- CTMX Strong Buy
- AEXA
- Analyst Count
- CTMX 5
- AEXA 0
- Target Price
- CTMX $5.80
- AEXA N/A
- AVG Volume (30 Days)
- CTMX 3.0M
- AEXA 915.0K
- Earning Date
- CTMX 11-07-2025
- AEXA 01-01-0001
- Dividend Yield
- CTMX N/A
- AEXA N/A
- EPS Growth
- CTMX 263.20
- AEXA N/A
- EPS
- CTMX 0.49
- AEXA N/A
- Revenue
- CTMX $141,100,000.00
- AEXA N/A
- Revenue This Year
- CTMX N/A
- AEXA N/A
- Revenue Next Year
- CTMX N/A
- AEXA N/A
- P/E Ratio
- CTMX $6.79
- AEXA N/A
- Revenue Growth
- CTMX 18.01
- AEXA N/A
- 52 Week Low
- CTMX $0.40
- AEXA $10.53
- 52 Week High
- CTMX $3.91
- AEXA $11.91
- Technical
- Relative Strength Index (RSI)
- CTMX 57.06
- AEXA N/A
- Support Level
- CTMX $3.21
- AEXA N/A
- Resistance Level
- CTMX $3.50
- AEXA N/A
- Average True Range (ATR)
- CTMX 0.25
- AEXA 0.00
- MACD
- CTMX -0.06
- AEXA 0.00
- Stochastic Oscillator
- CTMX 35.42
- AEXA 0.00
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About AEXA American Exceptionalism Acquisition Corp. A
American Exceptionalism Acquisition Corp A is a blank check company.